Login to Your Account



Transgene, Roche Enter Potential $293M Alliance On HPV Vaccine

By Jim Shrine


Thursday, April 12, 2007
Transgene SA entered its first product-development deal, a collaboration worth up to €218 million (US$293) on its late-stage therapeutic vaccine against human papillomavirus-related diseases. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription